SchillingerMSabetiSLoeweCet al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
2.
SchillingerMSabetiSDickPet al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.
3.
DickPWallnerHSabetiSet al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090–1095.
4.
LairdJRKatzenBTScheinertDet al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.
5.
Rocha-SinghKJBosiersMSchultzGet al. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. Catheter Cardiovasc Interv. 2015;86:164–170.
6.
JensSConijnAPKoelemayMJet al. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: Above the knee). Eur J Vasc Endovasc Surg. 2014;47:524–535.
7.
AboyansVRiccoJBBartelinkMELet al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
8.
AndersonJLHalperinJLAlbertNMet al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:1425–1443.
9.
Society for Vascular Surgery Lower Extremity Guidelines Writing Group, ConteMSPomposelliFBet al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 suppl):2S–41S.
10.
IidaOUrasawaKYasuoKet al. Self-expanding nitinol stent vs percutaneous transluminal angioplasty in the treatment of femoropopliteal lesions: 3-year data from the SM-01 trial. J Endovasc Ther. 2019;26:158–167.
11.
ArmstrongEJSaeedHAlvandiBet al. Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther. 2014;21:34–43.
12.
TosakaASogaYIidaOet al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23.
13.
YeoKKMalikULairdJR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv. 2011;78:604–608.
14.
HoffmannRMintzGSPopmaJJet al. Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. J Am Coll Cardiol. 1996;28:1134–1139.
15.
HoffmannRMintzGSDussaillantGRet al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247–1254.
16.
RichterGMPalmazJCNoeldgeGet al. Relationship between blood flow, thrombus, and neointima in stents. J Vasc Interv Radiol. 1999;10:598–604.
17.
DakeMDAnselGMJaffMRet al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
18.
ScheinertDScheinertSSaxJet al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315.
19.
KleberFXSchulzAWaliszewskiMet al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015;104:217–225.
20.
ZellerTLanghoffRRocha-SinghKJet al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017;10:e004848. doi:10.1161/CIRCINTERVENTIONS.116.004848.
21.
ShammasNWBanerjeeS.Should we routinely stent the femoropopliteal artery? an interventionalist’s perspective. J Invasive Cardiol. 2015;27:E258–E261.
22.
IidaOUematsuMSogaYet al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611–617.
23.
SchneiderPALairdJRTepeGet al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.
24.
TepeGSchnorrBAlbrechtTet al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.
25.
SchmidtAPiorkowskiMGornerHet al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
26.
GeraghtyPJMewissenMWJaffMRet al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386–395.e4.
27.
ShimadaYKinoNTonomuraDet al. Efficacy of cutting balloon angioplasty for chronic total occlusion of femoropopliteal arteries. Ann Vasc Surg. 2019. In press.
28.
ArmstrongEJChenDCWestinGGet al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697.
29.
NorgrenLHiattWRDormandyJAet al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
